Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-10P** is a pseudogene corresponding to a member of the U6 small nuclear RNA (snRNA) family, specifically a processed pseudogene for U6 snRNA. U6 snRNA itself is an essential non-coding RNA involved in the spliceosome for pre-mRNA splicing, but pseudogenes such as RNU6-10P are generally considered non-functional genetic elements that do not produce active RNA or protein. There is no evidence that RNU6-10P plays a direct biological, therapeutic, or disease-modifying role, nor is it a drug target[1]. **Context and explanation:** - RNU6-10P, according to genomic databases, is classified as a *pseudogene*, not an active gene or protein-coding locus[1]. - Functional U6 snRNAs are integral in splicing, a fundamental process in gene expression[2][5][6], but RNU6-10P—being a pseudogene—does not contribute directly to this function in humans. - Pseudogenes like RNU6-10P are sometimes included in annotations but are not therapeutic targets or biomarker candidates, and are therefore not classified as receptors, enzymes, transporters, transcription factors, etc.[1]. - There are no known drugs, disease links, or safety concerns associated with RNU6-10P, nor is it used as a reference biomarker (unlike functional U6 snRNA genes, which sometimes are used as housekeeping genes in qPCR, but these are not pseudogenes)[4]. **Key points:** - **RNU6-10P is a pseudogene, not an active RNA or protein** - **It has no established biological function or therapeutic/diagnostic relevance** - **Should not be classified as a drug/therapeutic target** - **Its inclusion may indicate a mistaken gene selection if looking for functional or targetable molecules**
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 10, pseudogene (RNU6-10P).